{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T16:54:56Z","timestamp":1787763296208,"version":"build-2784847793"},"reference-count":118,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2023,3,7]],"date-time":"2023-03-07T00:00:00Z","timestamp":1678147200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Natriuretic peptides (NPs) are the principal expression products of the endocrine function of the heart. They exert several beneficial effects, mostly mediated through guanylate cyclase-A coupled receptors, including natriuresis, diuresis, vasorelaxation, blood volume and blood pressure reduction, and regulation of electrolyte homeostasis. As a result of their biological functions, NPs counterbalance neurohormonal dysregulation in heart failure and other cardiovascular diseases. NPs have been also validated as diagnostic and prognostic biomarkers in cardiovascular diseases such as atrial fibrillation, coronary artery disease, and valvular heart disease, as well as in the presence of left ventricular hypertrophy and severe cardiac remodeling. Serial measurements of their levels may be used to contribute to more accurate risk stratification by identifying patients who are more likely to experience death from cardiovascular causes, heart failure, and cardiac hospitalizations and to guide tailored pharmacological and non-pharmacological strategies with the aim to improve clinical outcomes. On these premises, multiple therapeutic strategies based on the biological properties of NPs have been attempted to develop new targeted cardiovascular therapies. Apart from the introduction of the class of angiotensin receptor\/neprilysin inhibitors to the current management of heart failure, novel promising molecules including M-atrial natriuretic peptide (a novel atrial NP-based compound) have been tested for the treatment of human hypertension with promising results. Moreover, different therapeutic strategies based on the molecular mechanisms involved in NP regulation and function are under development for the management of heart failure, hypertension, and other cardiovascular conditions.<\/jats:p>","DOI":"10.3390\/ijms24065131","type":"journal-article","created":{"date-parts":[[2023,3,8]],"date-time":"2023-03-08T02:30:23Z","timestamp":1678242623000},"page":"5131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Natriuretic Peptides: It Is Time for Guided Therapeutic Strategies Based on Their Molecular Mechanisms"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4845-117X","authenticated-orcid":false,"given":"Giovanna","family":"Gallo","sequence":"first","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant\u2019Andrea Hospital, Via di Grottarossa 1035, 00189 Rome, RM, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9808-7970","authenticated-orcid":false,"given":"Speranza","family":"Rubattu","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant\u2019Andrea Hospital, Via di Grottarossa 1035, 00189 Rome, RM, Italy"},{"name":"IRCCS Neuromed, Via Atinense 18, 86077 Pozzilli, IS, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camillo","family":"Autore","sequence":"additional","affiliation":[{"name":"IRCCS San Raffaele Cassino, Via G. Di Biasio 1, 03043 Cassino, FR, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Volpe","sequence":"additional","affiliation":[{"name":"Department of Clinical and Molecular Medicine, Sapienza University of Rome, Sant\u2019Andrea Hospital, Via di Grottarossa 1035, 00189 Rome, RM, Italy"},{"name":"IRCCS San Raffaele Roma, Via della Pisana 235, 00163 Rome, RM, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1093\/eurheartj\/ehac759","article-title":"Endocrine functions of the heart: From bench to bedside","volume":"44","author":"Volpe","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/eurheartj\/eht466","article-title":"Natriuretic peptides in cardiovascular diseases: Current use and perspectives","volume":"35","author":"Volpe","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1038\/s41569-020-0381-0","article-title":"Cardiac natriuretic peptides","volume":"17","author":"Goetze","year":"2020","journal-title":"Nat. Rev. Cardiol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJM199807303390507","article-title":"Natriuretic peptides","volume":"339","author":"Levin","year":"1998","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/j.peptides.2004.09.024","article-title":"Biology of natriuretic peptides and their receptors","volume":"26","author":"Pandey","year":"2005","journal-title":"Peptides"},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Forte, M., Madonna, M., Schiavon, S., Valenti, V., Versaci, F., Zoccai, G.B., Frati, G., and Sciarretta, S. (2019). Cardiovascular Pleiotropic Effects of Natriuretic Peptides. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20163874"},{"key":"ref_7","first-page":"H1977","article-title":"Characterization of natriuretic peptide production by adult heart atria","volume":"276","author":"Ogawa","year":"1999","journal-title":"Am. J. Physiol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Lugnier, C., Meyer, A., Charloux, A., Andr\u00e8s, E., G\u00e9ny, B., and Talha, S. (2019). The Endocrine Function of the Heart: Physiology and Involvements of Natriuretic Peptides and Cyclic Nucleotide Phosphodiesterases in Heart Failure. J. Clin. Med., 8.","DOI":"10.3390\/jcm8101746"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1210\/endo.133.3.8365374","article-title":"Stretch-induced atrial natriuretic factor release utilizes a rapidly depleting pool of newly synthesized hormone","volume":"133","author":"Mangat","year":"1993","journal-title":"Endocrinology"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cardiores.2005.06.008","article-title":"Mechanisms of atrial natriuretic peptide secretion from the atrium","volume":"68","author":"Dietz","year":"2005","journal-title":"Cardiovasc. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1373\/clinchem.2010.143883","article-title":"Processing of pro-B-type natriuretic peptide: Furin and corin as candidate convertases","volume":"56","author":"Semenov","year":"2010","journal-title":"Clin. Chem."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1016\/j.amjcard.2017.06.030","article-title":"Differences in Natriuretic Peptide Levels by Race\/Ethnicity (From the Multi-Ethnic Study of Atherosclerosis)","volume":"120","author":"Gupta","year":"2017","journal-title":"Am. J. Cardiol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1161\/CIRCRESAHA.119.315026","article-title":"Race, Natriuretic Peptides, and High-Carbohydrate Challenge: A Clinical Trial","volume":"125","author":"Patel","year":"2019","journal-title":"Circ. Res."},{"key":"ref_14","first-page":"H1684","article-title":"Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure","volume":"274","author":"Luchner","year":"1998","journal-title":"Am. J. Physiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1016\/j.humpath.2012.04.023","article-title":"Diagnostic contribution of left ventricular endomyocardial biopsy in patients with clinical phenotype of hypertrophic cardiomyopathy","volume":"44","author":"Frustaci","year":"2013","journal-title":"Hum. Pathol."},{"key":"ref_16","first-page":"1294","article-title":"New insights into the mechanism of the elevation of plasma brain natriuretic polypeptide levels in patients with left ventricular hypertrophy","volume":"18","author":"Murakami","year":"2002","journal-title":"Can. J. Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.healun.2004.06.023","article-title":"Neuroendocrine profiling of humans receiving cardiac allografts","volume":"24","author":"Ogawa","year":"2005","journal-title":"J. Heart Lung Transplant."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1161\/01.CIR.100.3.287","article-title":"Discoordinate modulation of natriuretic peptides during acute cardiac allograft rejection in humans","volume":"100","author":"Masters","year":"1999","journal-title":"Circulation"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/nm.3128","article-title":"GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure","volume":"19","author":"Kim","year":"2013","journal-title":"Nat. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e006570","DOI":"10.1161\/CIRCHEARTFAILURE.119.006570","article-title":"Inflammation and Circulating Natriuretic Peptide Levels","volume":"13","author":"Ferguson","year":"2020","journal-title":"Circ. Heart Fail."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1136\/hrt.76.3_Suppl_3.36","article-title":"The renin-angiotensin-aldosterone system and the cardiac natriuretic peptides","volume":"76","author":"Richards","year":"1996","journal-title":"Heart"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2840","DOI":"10.2337\/db17-0392","article-title":"Atrial Natriuretic Peptide Affects Stimulus-Secretion Coupling of Pancreatic \u03b2-Cells","volume":"66","author":"Undank","year":"2017","journal-title":"Diabetes"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1128\/MCB.21.4.1173-1184.2001","article-title":"Regulation of mitogen-activated protein kinases in cardiac myocytes through the small G protein Rac1","volume":"21","author":"Clerk","year":"2001","journal-title":"Mol. Cell. Biol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/path.4234","article-title":"Epigenetics and chromatin remodeling in adult cardiomyopathy","volume":"231","author":"Mahmoud","year":"2013","journal-title":"J. Pathol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI61084","article-title":"HDAC4 controls histone methylation in response to elevated cardiac load","volume":"123","author":"Hohl","year":"2013","journal-title":"J. Clin. Investig."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/fgene.2018.00014","article-title":"The Histone Demethylase JMJD2A Modulates the Induction of Hypertrophy Markers in iPSC-Derived Cardiomyocytes","volume":"9","author":"Rosales","year":"2018","journal-title":"Front. Genet."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1016\/j.athoracsur.2017.04.046","article-title":"Histone Modification Is Correlated with Reverse Left Ventricular Remodeling in Nonischemic Dilated Cardiomyopathy","volume":"104","author":"Ito","year":"2017","journal-title":"Ann. Thorac. Surg."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1007\/s00438-013-0734-z","article-title":"miRNA-transcription factor interactions: A combinatorial regulation of gene expression","volume":"288","author":"Arora","year":"2013","journal-title":"Mol. Genet. Genom."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1016\/j.jacc.2015.11.049","article-title":"Acute Metabolic Influences on the Natriuretic Peptide System in Humans","volume":"67","author":"Arora","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.1128\/MCB.01114-15","article-title":"Novel MicroRNA Regulators of Atrial Natriuretic Peptide Production","volume":"36","author":"Wu","year":"2016","journal-title":"Mol. Cell. Biol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1038\/ng.328","article-title":"Association of common variants in NPPA and NPPB with circulating natriuretic peptides and blood pressure","volume":"41","author":"Larson","year":"2009","journal-title":"Nat. Genet."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/j.jacc.2011.05.011","article-title":"A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community","volume":"58","author":"Cannone","year":"2011","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.2337\/dc12-2337","article-title":"The atrial natriuretic peptide genetic variant rs5068 is associated with a favorable cardiometabolic phenotype in a Mediterranean population","volume":"36","author":"Cannone","year":"2013","journal-title":"Diabetes Care"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e130978","DOI":"10.1172\/jci.insight.130978","article-title":"Antisense regulation of atrial natriuretic peptide expression","volume":"4","author":"Celik","year":"2019","journal-title":"JCI Insight"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"693099","DOI":"10.3389\/fphys.2021.693099","article-title":"Molecular Signaling Mechanisms and Function of Natriuretic Peptide Receptor-A in the Pathophysiology of Cardiovascular Homeostasis","volume":"12","author":"Pandey","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"38693","DOI":"10.1074\/jbc.M304098200","article-title":"Atrial natriuretic peptide induces natriuretic peptide receptor-cGMP-dependent protein kinase interaction","volume":"278","author":"Airhart","year":"2003","journal-title":"J. Biol. Chem."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"4039","DOI":"10.1172\/JCI74281","article-title":"Endothelial C-type natriuretic peptide maintains vascular homeostasis","volume":"124","author":"Moyes","year":"2014","journal-title":"J. Clin. Investig."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.jacc.2016.04.060","article-title":"A Test in Context: Neprilysin: Function, Inhibition, and Biomarker","volume":"68","author":"Barallat","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1038\/ki.1996.491","article-title":"Blunted cGMP response to agonists and enhanced glomerular cyclic 3\u2032,5\u2032-nucleotide phosphodiesterase activities in experimental congestive heart failure","volume":"50","author":"Supaporn","year":"1996","journal-title":"Kidney Int."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/pr.110.002907","article-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action","volume":"62","author":"Francis","year":"2010","journal-title":"Pharmacol. Rev."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1111\/bph.12959","article-title":"The cGMP\/PKG pathway as a common mediator of cardioprotection: Translatability and mechanism","volume":"172","author":"Inserte","year":"2015","journal-title":"Br. J. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1161\/HYPERTENSIONAHA.116.08219","article-title":"Endothelium-Derived C-Type Natriuretic Peptide Contributes to Blood Pressure Regulation by Maintaining Endothelial Integrity","volume":"69","author":"Nakao","year":"2017","journal-title":"Hypertension"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1054576","DOI":"10.3389\/fcvm.2022.1054576","article-title":"Endothelial cell dysfunction: Implications for the pathogenesis of peripheral artery disease","volume":"9","author":"Kavurma","year":"2022","journal-title":"Front. Cardiovasc. Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e000536","DOI":"10.1161\/JAHA.113.000536","article-title":"The cGMP signaling pathway as a therapeutic target in heart failure with preserved ejection fraction","volume":"2","author":"Greene","year":"2013","journal-title":"J. Am. Heart Assoc."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1093\/cvr\/cvu163","article-title":"Delayed phospholamban phosphorylation in post-conditioned heart favours Ca2+ normalization and contributes to protection","volume":"103","author":"Inserte","year":"2014","journal-title":"Cardiovasc. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/cvr\/cvab245","article-title":"Natriuretic peptide receptor B maintains heart rate and sinoatrial node function via cyclic GMP-mediated signalling","volume":"118","author":"Dorey","year":"2022","journal-title":"Cardiovasc. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00109-011-0801-z","article-title":"Molecular mechanisms underlying cardiac antihypertrophic and antifibrotic effects of natriuretic peptides","volume":"90","author":"Calvieri","year":"2012","journal-title":"J. Mol. Med."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0006-291X(02)00807-0","article-title":"Induction of IkappaB: Atrial natriuretic peptide as a regulator of the NF-kappaB pathway","volume":"295","author":"Kiemer","year":"2002","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"643721","DOI":"10.3389\/fphys.2021.643721","article-title":"A Contemporary View of Natriuretic Peptides in the SARS-CoV-2 Era","volume":"12","author":"Rubattu","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1126\/science.7839143","article-title":"Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension","volume":"267","author":"John","year":"1995","journal-title":"Science"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/j.bbadis.2009.09.009","article-title":"Influence of natriuretic peptide receptor-1 on survival and cardiac hypertrophy during development","volume":"1792","author":"Scott","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/j.jacc.2005.12.081","article-title":"Association of atrial natriuretic peptide and type a natriuretic peptide receptor gene polymorphisms with left ventricular mass in human essential hypertension","volume":"48","author":"Rubattu","year":"2006","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"4239","DOI":"10.1073\/pnas.070371497","article-title":"Cardiac fibrosis in mice lacking brain natriuretic peptide","volume":"97","author":"Tamura","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"5121","DOI":"10.1007\/s00018-020-03573-0","article-title":"Epigenetic control of natriuretic peptides: Implications for health and disease","volume":"77","author":"Rubattu","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1161\/CIRCULATIONAHA.110.981720","article-title":"Long-term cardiac pro-B-type natriuretic peptide gene delivery prevents the development of hypertensive heart disease in spontaneously hypertensive rats","volume":"123","author":"Cataliotti","year":"2011","journal-title":"Circulation"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"e155640","DOI":"10.1172\/jci.insight.155640","article-title":"Mutant ANP induces mitochondrial and ion channel remodeling in a human iPSC-derived atrial fibrillation model","volume":"7","author":"Ly","year":"2022","journal-title":"JCI Insight"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.yjmcc.2009.07.020","article-title":"Augmented potassium current is a shared phenotype for two genetic defects associated with familial atrial fibrillation","volume":"48","author":"Abraham","year":"2010","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Forte, M., Marchitti, S., Di Nonno, F., Stanzione, R., Schirone, L., Cotugno, M., Bianchi, F., Schiavon, S., Raffa, S., and Ranieri, D. (2022). NPPA\/atrial natriuretic peptide is an extracellular modulator of autophagy in the heart. Autophagy, Online ahead of print.","DOI":"10.1080\/15548627.2022.2115675"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e003601","DOI":"10.1161\/JAHA.116.003601","article-title":"MiR30-GALNT1\/2 Axis-Mediated Glycosylation Contributes to the Increased Secretion of Inactive Human Prohormone for Brain Natriuretic Peptide (proBNP) from Failing Hearts","volume":"6","author":"Nakagawa","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1113\/jphysiol.2007.144253","article-title":"Natriuretic peptide C receptor signalling in the heart and vasculature","volume":"586","author":"Rose","year":"2008","journal-title":"J. Physiol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1007\/s10557-020-06959-1","article-title":"Cardiac Cyclic Nucleotide Phosphodiesterases: Roles and Therapeutic Potential in Heart Failure","volume":"34","author":"Preedy","year":"2020","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1056\/NEJMoa2211680","article-title":"Trial of an Intervention to Improve Acute Heart Failure Outcomes","volume":"388","author":"Lee","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Pedicino, D., and Volpe, M. (2023). Improving care for heart failure patients by COACHing clinicians to use decision-support tools. Eur. Heart J., in press.","DOI":"10.1093\/eurheartj\/ehad097"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1136\/heartjnl-2011-300823","article-title":"Serial measurements of midregion proANP and copeptin in ambulatory patients with heart failure: Incremental prognostic value of novel biomarkers in heart failure","volume":"98","author":"Miller","year":"2012","journal-title":"Heart"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Jia, X., Al Rifai, M., Hoogeveen, R., Echouffo-Tcheugui, J.B., Shah, A.M., Ndumele, C.E., Virani, S.S., Bozkurt, B., Selvin, E., and Ballantyne, C.M. (2023). Association of Long-term Change in N-Terminal Pro-B-Type Natriuretic Peptide with Incident Heart Failure and Death. JAMA Cardiol., Online ahead of print.","DOI":"10.1001\/jamacardio.2022.5309"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/ndt\/16.7.1459","article-title":"Long-term CAPD patients are volume expanded and display more severe left ventricular hypertrophy than haemodialysis patients","volume":"16","author":"Enia","year":"2001","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.4065\/76.11.1111","article-title":"Circulating natriuretic peptide concentrations in patients with end-stage renal disease: Role of brain natriuretic peptide as a biomarker for ventricular remodeling","volume":"76","author":"Cataliotti","year":"2001","journal-title":"Mayo Clin. Proc."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1046\/j.1523-1755.2001.0590041559.x","article-title":"The Cardiovascular Risk Extended Evaluation. Diagnostic potential of cardiac natriuretic peptides in dialysis patients","volume":"59","author":"Mallamaci","year":"2001","journal-title":"Kidney Int."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1161\/HYPERTENSIONAHA.110.163550","article-title":"N-terminal pro-brain natriuretic peptide: A powerful predictor of mortality in hypertension","volume":"57","author":"Paget","year":"2011","journal-title":"Hypertension"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"H1529","DOI":"10.1152\/ajpheart.00107.2006","article-title":"Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy","volume":"291","author":"Belluardo","year":"2006","journal-title":"Am. J. Physiol. Heart Circ. Physiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/j.jacc.2012.05.049","article-title":"Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP","volume":"60","author":"Macheret","year":"2012","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"e004851","DOI":"10.1161\/JAHA.116.004851","article-title":"Repeated Measurements of Cardiac Biomarkers in Atrial Fibrillation and Validation of the ABC Stroke Score Over Time","volume":"6","author":"Hijazi","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.atherosclerosis.2009.01.033","article-title":"Human coronary atherosclerosis modulates cardiac natriuretic peptide release","volume":"206","author":"Barbato","year":"2009","journal-title":"Atherosclerosis"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.ijcard.2011.11.057","article-title":"NT-proANP circulating level is a prognostic marker in stable ischemic heart disease","volume":"155","author":"Barbato","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e024616","DOI":"10.1161\/JAHA.121.024616","article-title":"B-Type Natriuretic Peptide and Long-Term Cardiovascular Mortality in Patients with Coronary Heart Disease","volume":"11","author":"Stewart","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.yjmcc.2019.03.011","article-title":"Molecular and clinical implications of natriuretic peptides in aortic valve stenosis","volume":"129","author":"Gallo","year":"2019","journal-title":"J. Mol. Cell. Cardiol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Gallo, G., Forte, M., Stanzione, R., Cotugno, M., Bianchi, F., Marchitti, S., Berni, A., Volpe, M., and Rubattu, S. (2020). Functional Role of Natriuretic Peptides in Risk Assessment and Prognosis of Patients with Mitral Regurgitation. J. Clin. Med., 9.","DOI":"10.3390\/jcm9051348"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Helgeson, S.A., Imam, J.S., Moss, J.E., Hodge, D.O., and Burger, C.D. (2018). Comparison of Brain Natriuretic Peptide Levels to Simultaneously Obtained Right Heart Hemodynamics in Stable Outpatients with Pulmonary Arterial Hypertension. Diseases, 6.","DOI":"10.3390\/diseases6020033"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","article-title":"Predicting survival in pulmonary arterial hypertension: Insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL)","volume":"122","author":"Benza","year":"2010","journal-title":"Circulation"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"771","DOI":"10.2459\/JCM.0000000000000852","article-title":"Atrial natriuretic peptide predicts disease progression and digital ulcers development in systemic sclerosis patients","volume":"20","author":"Romaniello","year":"2019","journal-title":"J. Cardiovasc. Med."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1080\/1744666X.2021.1908888","article-title":"Circulating NT-proANP level is a predictor of mortality for systemic sclerosis: A retrospective study of an Italian cohort","volume":"17","author":"Romaniello","year":"2021","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1681\/ASN.V1271508","article-title":"Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients","volume":"12","author":"Zoccali","year":"2001","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.jacc.2016.09.931","article-title":"Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Heart Failure","volume":"68","author":"Zile","year":"2016","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.jacc.2019.01.018","article-title":"B-Type Natriuretic Peptide during Treatment with Sacubitril\/Valsartan: The PARADIGM-HF Trial","volume":"73","author":"Myhre","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/ejhf.1670","article-title":"TRANSITION Investigators. Initiation of sacubitril\/valsartan shortly after hospitalisation for acutely decompensated heart failure in patients with newly diagnosed (de novo) heart failure: A subgroup analysis of the TRANSITION study","volume":"22","author":"Senni","year":"2020","journal-title":"Eur. J. Heart Fail."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"e007034","DOI":"10.1161\/CIRCHEARTFAILURE.120.007034","article-title":"2 Efficacy and Safety of Sacubitril\/Valsartan in High-Risk Patients in the PIONEER-HF Trial","volume":"14","author":"Berg","year":"2021","journal-title":"Circ. Heart Fail."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1002\/ejhf.548","article-title":"Initiating sacubitril\/valsartan (LCZ696) in heart failure: Results of TITRATION, a double-blind, randomized comparison of two uptitration regimens","volume":"18","author":"Senni","year":"2016","journal-title":"Eur. J. Heart Fail."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1908655","article-title":"PARAGON-HF Investigators and Committees. Angiotensin-Neprilysin Inhibition in Heart Failure with Preserved Ejection Fraction","volume":"381","author":"Solomon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1161\/CIRCULATIONAHA.119.044586","article-title":"Sacubitril\/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure","volume":"141","author":"Solomon","year":"2020","journal-title":"Circulation"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijcard.2020.11.071","article-title":"Sacubitril\/valsartan for the management of heart failure: A perspective viewpoint on current evidence","volume":"327","author":"Volpe","year":"2021","journal-title":"Int. J. Cardiol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"652163","DOI":"10.3389\/fphys.2021.652163","article-title":"Sacubitril\/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction Spectrum","volume":"12","author":"Gallo","year":"2021","journal-title":"Front. Physiol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"1845","DOI":"10.1056\/NEJMoa2104508","article-title":"PARADISE-MI Investigators and Committees. Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction","volume":"385","author":"Pfeffer","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1918","DOI":"10.1002\/ejhf.2663","article-title":"Sacubitril\/valsartan versus ramipril for patients with acute myocardial infarction: Win-ratio analysis of the PARADISE-MI trial","volume":"24","author":"Berwanger","year":"2022","journal-title":"Eur. J. Heart Fail."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1001\/jama.2019.12821","article-title":"PROVE-Hf Investigators. Association of change in N-terminal pro-B-type natriuretic peptide following initiation of sacubitril-valsartan treatment with cardiac structure and function in patients with heart failure with reduced ejection fraction","volume":"322","author":"Januzzi","year":"2019","journal-title":"JAMA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1001\/jama.2019.12843","article-title":"Effect of Sacubitril-Valsartan vs. Enalapril on Aortic Stiffness in Patients with Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial","volume":"322","author":"Desai","year":"2019","journal-title":"JAMA"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jacc.2018.11.042","article-title":"Effects of Sacubitril\/Valsartan on Biomarkers of Extracellular Matrix Regulation in Patients with HFrEF","volume":"73","author":"Zile","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35065611","article-title":"NO independent regulatory site on soluble guanylate cyclase","volume":"410","author":"Stasch","year":"2001","journal-title":"Nature"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S0014-2999(03)01674-1","article-title":"Mechanisms of nitric oxide independent activation of soluble guanylyl cyclase","volume":"468","author":"Schmidt","year":"2003","journal-title":"Eur. J. Pharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/HYPERTENSIONAHA.106.083832","article-title":"Targeting heme-oxidized soluble guanylate cyclase in experimental heart failure","volume":"49","author":"Boerrigter","year":"2007","journal-title":"Hypertension"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1056\/NEJMoa1915928","article-title":"Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction","volume":"382","author":"Armstrong","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s40292-021-00489-z","article-title":"Targeting Cyclic Guanylate Monophosphate in Resistant Hypertension and Heart Failure: Are Sacubitril\/Valsartan and Vericiguat Synergistic and Effective in Both Conditions?","volume":"28","author":"Gallo","year":"2021","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40292-021-00483-5","article-title":"The Natriuretic Peptides for Hypertension Treatment","volume":"29","author":"Rubattu","year":"2022","journal-title":"High Blood Press. Cardiovasc. Prev."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1002\/ehf2.12305","article-title":"Acute heart failure management in the USA and Japan: Overview of practice patterns and review of evidence","volume":"5","author":"Tanaka","year":"2018","journal-title":"ESC Heart Fail."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.ahj.2008.10.002","article-title":"Standardizing care for acute decompensated heart failure in a large megatrial: The approach for the Acute Studies of Clinical Effectiveness of Nesiritide in Subjects with Decompensated Heart Failure (ASCEND-HF)","volume":"157","author":"Ezekowitz","year":"2009","journal-title":"Am. Heart J."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1093\/ehjcvp\/pvv040","article-title":"Cenderitide: Structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions","volume":"2","author":"Lee","year":"2016","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1161\/HYPERTENSIONAHA.121.17159","article-title":"First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"815796","DOI":"10.3389\/fphys.2021.815796","article-title":"Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension","volume":"12","author":"Cannone","year":"2022","journal-title":"Front. Physiol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1161\/HYPERTENSIONAHA.121.18264","article-title":"Novel ANP (Atrial Natriuretic Peptide)-Based Therapy for Hypertension: The Promising Role of a Disease Mechanism Targeted Approach","volume":"78","author":"Volpe","year":"2021","journal-title":"Hypertension"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1161\/HYPERTENSIONAHA.121.18906","article-title":"MANP Activation of the cGMP Inhibits Aldosterone via PDE2 and CYP11B2 in H295R Cells and in Mice","volume":"79","author":"Chen","year":"2022","journal-title":"Hypertension"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1161\/HYPERTENSIONAHA.120.14704","article-title":"Cardioprotective Effects of the Novel Compound Vastiras in a Preclinical Model of End-Organ Damage","volume":"75","author":"Altara","year":"2020","journal-title":"Hypertension"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1161\/01.CIR.0000124064.00494.21","article-title":"Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure","volume":"109","author":"Cataliotti","year":"2004","journal-title":"Circulation"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"R407","DOI":"10.1152\/ajpregu.00286.2017","article-title":"CRRL269: A novel designer and renal-enhancing pGC-A peptide activator","volume":"314","author":"Chen","year":"2018","journal-title":"Am. J. Physiol. Regul. Integr. Comp. Physiol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1161\/HYPERTENSIONAHA.118.12012","article-title":"Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide","volume":"73","author":"Meems","year":"2019","journal-title":"Hypertension"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"11282","DOI":"10.1073\/pnas.0811851106","article-title":"Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide","volume":"106","author":"Pan","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1021\/bc200592c","article-title":"Atrial natriuretic peptide-Fc, ANP-Fc, fusion proteins: Semisynthesis, in vitro activity and pharmacokinetics in rats","volume":"23","author":"Mezo","year":"2012","journal-title":"Bioconjugate Chem."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"e2109386118","DOI":"10.1073\/pnas.2109386118","article-title":"Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators","volume":"118","author":"Sangaralingham","year":"2021","journal-title":"Proc. Natl. Acad. Sci. USA"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:50:10Z","timestamp":1760122210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/6\/5131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,7]]},"references-count":118,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["ijms24065131"],"URL":"https:\/\/doi.org\/10.3390\/ijms24065131","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,7]]}}}